Novavax, King sales and marketing update

The companies expanded their January licensing deal under which KG received an exclusive license to market Estrasorb worldwide, excluding the U.S., Canada, Italy, the Netherlands, Greece, Switzerland and Spain (see BioCentury, Jan. 16). As expanded, KG will have exclusive rights in all territories except the U.S. NOX will receive $3 million in upfront licensing fees, $1 million upon Canadian approval and $2 million upon the first approval in one of the added European countries. ...